verapamil has been researched along with Lymphoma, Non-Hodgkin in 8 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dexverapamil was escalated eight dose levels, from 240 to 1,200 mg/m2/d." | 6.68 | Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. ( Bates, SE; Bryant, G; Fojo, A; Herdt, J; Jaffe, ES; Regis, J; Steinberg, SM; Wilson, WH; Wittes, RE; Zhan, Z, 1995) |
| "The B-cell neoplasms, multiple myeloma and non-Hodgkin's lymphoma, frequently become drug resistant, despite initial responses to chemotherapeutic drugs." | 5.28 | Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. ( Dalton, WS; Durie, BG; Grogan, TM; Meltzer, PS; Miller, TP; Salmon, SE; Scheper, RJ; Taylor, CW, 1989) |
| "Dexverapamil was escalated eight dose levels, from 240 to 1,200 mg/m2/d." | 2.68 | Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. ( Bates, SE; Bryant, G; Fojo, A; Herdt, J; Jaffe, ES; Regis, J; Steinberg, SM; Wilson, WH; Wittes, RE; Zhan, Z, 1995) |
| "The B-cell neoplasms, multiple myeloma and non-Hodgkin's lymphoma, frequently become drug resistant, despite initial responses to chemotherapeutic drugs." | 1.28 | Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. ( Dalton, WS; Durie, BG; Grogan, TM; Meltzer, PS; Miller, TP; Salmon, SE; Scheper, RJ; Taylor, CW, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biscardi, M | 1 |
| Teodori, E | 1 |
| Caporale, R | 1 |
| Budriesi, R | 1 |
| Balestri, F | 1 |
| Scappini, B | 1 |
| Gavazzi, S | 1 |
| Grossi, A | 1 |
| Wilson, WH | 2 |
| Bates, SE | 2 |
| Fojo, A | 1 |
| Bryant, G | 1 |
| Zhan, Z | 2 |
| Regis, J | 2 |
| Wittes, RE | 1 |
| Jaffe, ES | 1 |
| Steinberg, SM | 1 |
| Herdt, J | 1 |
| Tidefelt, U | 1 |
| Juliusson, G | 1 |
| Elmhorn-Rosenborg, A | 1 |
| Peterson, C | 2 |
| Paul, C | 1 |
| Fojo, AT | 1 |
| Alvarez, M | 1 |
| Robey, R | 1 |
| Hose, C | 1 |
| Monks, A | 1 |
| Kang, YK | 1 |
| Chabner, B | 1 |
| Gaynor, ER | 1 |
| Unger, JM | 1 |
| Miller, TP | 2 |
| Grogan, TM | 2 |
| White, LA | 1 |
| Mills, GM | 1 |
| Balcerzak, SP | 1 |
| Varterasian, M | 1 |
| LeBlanc, M | 1 |
| Fisher, RI | 1 |
| Laine, K | 1 |
| Valavaara, R | 1 |
| Rouru, J | 1 |
| Dalton, WS | 1 |
| Meltzer, PS | 1 |
| Scheper, RJ | 1 |
| Durie, BG | 1 |
| Taylor, CW | 1 |
| Salmon, SE | 1 |
| Reizenstein, P | 1 |
| Kapoor, R | 1 |
| Gruber, A | 1 |
1 review available for verapamil and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Clinical reversal of multidrug resistance.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Membe | 1996 |
2 trials available for verapamil and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 1995 |
Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free Surviv | 2001 |
5 other studies available for verapamil and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Multidrug reverting activity toward leukemia cells in a group of new verapamil analogues with low cardiovascular activity.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Arrhythmia Agents; Antibiotics, Antineoplastic; Aorta; | 2006 |
Increased intracellular concentrations of doxorubicin in resistant lymphoma cells in vivo by concomitant therapy with verapamil and cyclosporin A.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Doxorubicin; Drug Interactions; | 1994 |
[Drug interaction behind the toxicity of chemotherapy].
Topics: Aged; Anti-Arrhythmia Agents; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; C | 1998 |
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter | 1989 |
Accumulation of vincristine and doxorubicin in malignant lymphocytes with different immunophenotypes.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; B-Lymphocytes; Doxorubicin; Female; Fluorescent Ant | 1989 |